Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
5 FDA decisions to watch in the second quarter
BioPharma Dive
Mon, 04/3/23 - 11:06 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
Endpoints
Thu, 03/30/23 - 11:05 pm
Massachusetts
Biogen
Aduhelm
legal
Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study
BioSpace
Thu, 03/30/23 - 11:02 pm
Biogen
Alzheimer's disease
clinical trials
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Investors Business Daily
Thu, 03/23/23 - 09:58 am
Ionis Pharmaceuticals
Biogen
ALS
FDA
tofersen
FDA advisers support conditional clearance of Biogen’s ALS drug
BioPharma Dive
Wed, 03/22/23 - 09:23 pm
Biogen
ALS
FDA
tofersen
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
BioSpace
Mon, 03/20/23 - 11:40 am
ALS
Biogen
Ionis Pharmaceuticals
FDA
tofersen
clinical trials
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
BioSpace
Mon, 03/20/23 - 09:51 am
Sangamo Therapeutics
Novartis
Biogen
neurology
gene regulation therapies
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
Fri, 03/17/23 - 11:43 am
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Biogen's head of neurodegeneration leaves
Fierce Biotech
Fri, 03/17/23 - 10:03 am
Biogen
women executives
Aduhelm
Alzheimer's disease
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Seeking Alpha
Thu, 03/16/23 - 09:44 am
Biogen
EMA
Europe
MS
multiple sclerosis
Tecfidera
generics
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
Mon, 03/13/23 - 04:44 pm
VHA
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Sun, 03/12/23 - 09:40 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
Biogen names Stelios Papadopoulos' successor
Fierce Biotech
Fri, 03/10/23 - 09:45 am
Biogen
Stelios Papadopoulos
Caroline Dorsa
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Wed, 03/8/23 - 09:47 pm
Biogen
SAGE Therapeutics
FDA
zuranolone
major depressive disorder
postpartum depression
FDA sets July decision date for full approval of Leqembi
BioSpace
Mon, 03/6/23 - 12:11 pm
Eisai
Biogen
Alzheimer's disease
Leqembi
FDA
lecanemab
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Alzheimer's disease
Biogen
Eisai
Lundbeck
Otsuka
Avanir Pharmaceuticals
Axesome
Aduhelm
Leqembi
Go or no go? Vaccines and neurology up for discussion
EP Vantage
Tue, 02/28/23 - 11:05 am
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Billy Dunn, FDA’s top neuroscience official to depart agency
RAPS.org
Mon, 02/27/23 - 07:12 pm
Billy Dunn
FDA
Neurosciences
Biogen
Aduhelm
Medicare maintains limits on Eisai’s new Alzheimer’s drug
BioPharma Dive
Thu, 02/23/23 - 04:27 pm
Medicare
CMS
Eisai
Biogen
Leqembi
Alzheimer's disease
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »